NCT05481242

Brief Summary

This multi-center retrospective study collected clinical, laboratory, and CT pulmonary angiography parameters with acute pulmonary embolism patients from admission to predict adverse outcomes within 30 days after admission into hospital.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
8mo left

Started Jan 2011

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress96%
Jan 2011Dec 2026

Study Start

First participant enrolled

January 1, 2011

Completed
10.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2021

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

July 28, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 1, 2022

Completed
4.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Expected
Last Updated

March 11, 2026

Status Verified

March 1, 2026

Enrollment Period

10.1 years

First QC Date

July 28, 2022

Last Update Submit

March 8, 2026

Conditions

Pulmonary Embolism and ThrombosisDeterioration, Clinical

Outcome Measures

Primary Outcomes (1)

  • Adverse outcomes

    The endpoints of deterioration in this study were defined as the occurrence of any adverse clinical outcomes from medical records and follow-up within 30 days of admission such as death, mechanical ventilation, cardiopulmonary resuscitation, and the need for life-saving vasopressor or reperfusion treatment .In each centre, the researchers for evaluating endpoints were blind to collect and to measure study parameters.

    30 days

Secondary Outcomes (1)

  • Adverse outcomes

    2 years

Interventions

retrospective observational studyOTHER

retrospective observational study

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Chinese

You may qualify if:

  • age of ≥ 18 years and a pulmonary embolism diagnosis based on CT pulmonary angiography

You may not qualify if:

  • pregnancy
  • reception of reperfusion treatment before admission
  • missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shenjing Hospital of CHINA MEDICAL UNIVERSITY

Shenyang, Liaoning, China

Location

MeSH Terms

Conditions

Pulmonary EmbolismThrombosisClinical Deterioration

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesEmbolismEmbolism and ThrombosisVascular DiseasesCardiovascular DiseasesDisease ProgressionDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • DONG JIA

    Shenjing Hospital of CHINA MEDICAL UNIVERSITY

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

July 28, 2022

First Posted

August 1, 2022

Study Start

January 1, 2011

Primary Completion

January 31, 2021

Study Completion (Estimated)

December 31, 2026

Last Updated

March 11, 2026

Record last verified: 2026-03

Locations

CN(1)